Shares of Novo Nordisk NVO were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share rose 14.29% year over year to $0.64, which were in line with the estimate of $0.64.
Revenue of $5,142,000,000 up by 5.74% year over year, which missed the estimate of $5,350,000,000.
Looking Ahead
Novo Nordisk hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Feb 03, 2021
Time: 07:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/oeqkkcyq
Price Action
52-week high: $73.92
Company's 52-week low was at $49.24
Price action over last quarter: Up 9.13%
Company Profile
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.